60
603259.SHG WuXi AppTec Co Ltd
- Market cap
- CNY 471B
- P/E
- 15.7x
- P/B
- 4.66x
- ROE
- 26.7%
- Dividend yield
- 1.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603259.SHG undervalued?
Graham number603259.SHG trades 80.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
WuXi AppTec Co Ltd fundamental analysis
No fundamental analysis for WuXi AppTec Co Ltd yet.
WuXi AppTec Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About WuXi AppTec Co Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery t…
Full company profileWuXi AppTec Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
WuXi AppTec Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.12B | 7.77B | 9.61B | 12.9B | 16.5B | 22.9B | 39.4B | 38.7B | 37.9B | 43.4B | 60.7B |
| Gross Profit | 2.49B | 3.25B | 3.79B | 5.01B | 6.26B | 8.28B | 14.6B | 14.9B | 16.5B | 21.0B | 32.9B |
| Operating Income | 1.28B | 1.46B | 2.58B | 2.34B | 3.39B | 6.04B | 10.7B | 11.9B | 13.4B | 16.0B | 27.3B |
| EBITDA | 1.57B | 2.05B | 2.39B | 3.27B | 3.91B | 5.42B | 10.6B | 11.9B | 14.5B | 19.5B | 32.3B |
| Net Income | 975M | 1.23B | 2.26B | 1.85B | 2.96B | 5.10B | 8.81B | 9.61B | 9.45B | 19.2B | 25.9B |
| EPS | 0.46 | 0.55 | 0.94 | 0.67 | 1.04 | 1.73 | 2.82 | 3.24 | 3.26 | 6.59 | 8.52 |
| Balance Sheet | |||||||||||
| Total Assets | 10.6B | 12.6B | 23.4B | 29.2B | 46.3B | 55.1B | 64.7B | 73.7B | 80.3B | 103B | 125B |
| Total Liabilities | 4.53B | 5.84B | 4.82B | 11.8B | 13.6B | 16.4B | 17.8B | 18.2B | 21.2B | 22.9B | 27.7B |
| Shareholders' Equity | 5.57B | 6.34B | 17.7B | 17.3B | 32.5B | 38.5B | 46.6B | 55.1B | 58.6B | 79.7B | 96.8B |
| Cash & Short-term Investments | 3.95B | 2.78B | 7.92B | 6.97B | 14.9B | 8.77B | 9.42B | 13.8B | 19.6B | 42.3B | 37.1B |
| Total Debt | 493M | 1.64B | 1.85B | 7.52B | 5.93B | 5.62B | 6.99B | 5.45B | 4.75B | 8.42B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.76B | 1.79B | 1.64B | 2.92B | 3.97B | 4.59B | 10.6B | 13.4B | 12.4B | 17.6B | - |
| Capital Expenditure | 958M | 1.36B | 2.25B | 2.53B | 3.03B | 6.94B | 9.97B | 5.52B | 4.00B | 5.54B | 6.78B |
| Free Cash Flow | 799M | 430M | -608M | 384M | 943M | -2.35B | 650M | 7.87B | 8.40B | 12.1B | 16.1B |
| Ratios | |||||||||||
| ROE | 17.5% | 19.3% | 12.8% | 10.7% | 9.1% | 13.2% | 18.9% | 17.4% | 16.1% | 24.1% | 26.7% |
| ROA | 9.2% | 9.8% | 9.7% | 6.3% | 6.4% | 9.2% | 13.6% | 13.0% | 11.8% | 18.6% | 20.7% |
| Net Profit Margin | 15.9% | 15.8% | 23.5% | 14.4% | 17.9% | 22.3% | 22.4% | 24.8% | 24.9% | 44.2% | 42.6% |
| Debt to Equity | 0.09x | 0.26x | 0.10x | 0.43x | 0.18x | 0.15x | 0.15x | 0.10x | 0.08x | 0.11x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
WuXi AppTec Co Ltd dividends
- Dividend yield
- 1.04%
- Forward dividend
- 2.09 CNY
- Payout ratio
- 25.4%
- Ex-dividend date
- Sep 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 4.88B | 1.67 | 25.4% |
| 2024 | CNY 3.08B | 1.06 | 32.6% |
| 2023 | CNY 2.76B | 0.93 | 28.7% |
| 2022 | CNY 1.60B | 0.51 | 18.1% |
| 2021 | CNY 913M | 0.31 | 17.9% |
| 2020 | CNY 638M | 0.22 | 21.6% |
| 2019 | CNY 730M | 0.26 | 39.4% |
| 2018 | CNY 83.3M | 0.03 | 3.7% |
| 2017 | CNY 40.3M | 0.02 | 3.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 8, 2021.
Who owns WuXi AppTec Co Ltd
- Insiders 17.90%
- Institutions 23.65%
- Public & others 58.45%
- Shares outstanding 2.47B
- Free float 2.43B
WuXi AppTec Co Ltd company profile
- Company name
- WuXi AppTec Co Ltd
- Ticker
- 603259.SHG
- ISIN
- CNE1000031K4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 33,834
- Fiscal year end
- December
- Address
- 288 Fute Zhong Road, Shanghai, China, 200131
- Phone
- 86 21 5046 1111
- Website
- wuxiapptec.com
About WuXi AppTec Co Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
WuXi AppTec Co Ltd management
10- Dr. Ge Li Ph.D.Co-Founder, Executive Chairman, President & CEO · born 1967
- Dr. Minzhang Chen Ph.D.Co-CEO & Executive Director · born 1969
- Dr. Qing Yang Ph.D.Co-CEO & Executive Director · born 1969
- Ms. Ming ShiSenior VP & CFO · born 1974
- Mr. Zhaohui ZhangCOO of China, Executive VP & Executive Director · born 1969
- Mr. Ruijia TangIR Director
- Dr. Howard Wu J.D.Senior Vice President of Legal Department & Human Resources Department
- Mr. Tao Guo Ph.D.Senior Vice President of RCS IPM
- Dr. Youchu Wang Ph.D.Senior Vice President of API Early Phase Development
- Mr. Feng ZhangSenior Vice President of API Manufacturing · born 1977